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Background: A 50 cent prescription levy was introduced in 2010 on the General Medical Services (GMS) scheme
(Irish public health insurance). This study sought to examine patient attitudes and opinions surrounding the 50 cent
copayment. Given the small momentary value of the prescription fee, these results are of interest to policymakers
internationally who wish to reduce copayments rather than abolish them.
Methods: A qualitative research design was used; semi structured interviews were carried out. Twenty four GMS
eligible participants were interviewed in 23 interviews. Fifteen females and 9 males took part. Ages varied from
31- >70 years. Patients were invited to be interviewed in both independent and chain community pharmacies in
three types of setting; 1) a socially deprived urban area, 2) a suburban affluent area and 3) a rural area. The
Framework method was used for data management and analysis using QSR International’s NVivo 9.2 qualitative
data analysis software. The “Francis method” was used to test for data saturation.
Results: Results are of interest to the Irish context and also at a broader international level. Patients were mostly
accepting of the prescription levy with some reservations concerning an increased price and the way in which
generated revenue would be used by government. Participants identified waste of prescription drugs at the hand
of patients (moral hazard), but there was discordant opinion on whether the 50 cent copayment would halt this
moral hazard. Interviewees felt the levy was affordable, albeit some may suffer a financial impact more than others.
Conclusions: This qualitative study gives important insights into the experiences of GMS patients with regard to
the prescription levy. Information regarding the appropriateness of a 50 cent copayment as a symbolic copayment
needs to be confirmed by quantitative analysis. Further insight is required from a younger population.
Keywords: Qualitative research, Copayment, Health policy, Adherence, IrelandBackground
The General Medical Services (GMS) scheme in Ireland
is a tax funded, means tested, public health insurance
scheme [1]. The GMS scheme provides free hospital
care, GP services and prescription drugs to those who
qualify. Means tested thresholds differ for those under
and over 70 years, which results in almost 100% of those
over 70 years qualifying, along with low income and* Correspondence: s.sinnott@ucc.ie
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reproduction in any medium, provided the orsocial welfare dependent individuals [2]. Currently, 38%
(1,615,809) of the Irish population receive healthcare on
this scheme [3]. The remainder of the Irish population
are deemed to be “private” patients who either have pri-
vate health insurance plans or who pay out of pocket for
healthcare. Private health insurance plans in Ireland do
not entitle the holder to free GP care or prescriptions.
Instead, “private” patients can enroll on the government
provided Drugs Payment Scheme (DPS) which allows
patients to purchase drugs up to the value of €132/
month per family. After this ceiling is passed, the re-
mainder is reimbursed.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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copayment of 50 cent per prescription item was intro-
duced in October 2010, which was capped at €10 per
household monthly. Copayments generate cost savings via
reductions in moral hazard, which is wasteful use of a good
at the expense of a third party payer. In addition to savings,
additional revenue can be generated [4]. However, copay-
ments are not without their disadvantages. Copayments are
associated with decreased utilisation of medicines; this
decrease varies in magnitude according to cost of copay-
ment and also whether medicines are regarded as essential
or less-essential, the use of the latter being affected more
[5-8]. Essential medicines are generally understood to be
treatments that are important in disease progression and in
life prolongation, whereas less-essential drugs play a role
solely in symptom control [9]. Therefore it can be appre-
ciated how copayments are implicated in public health
concerns; the reduced use of essential medicines has been
associated with negative health outcomes for patients
[9-12]. Poor clinical outcomes result in increased use of
health services and increased expenditure overall [9-13].
Recently, there has been a move towards reducing finan-
cial barriers for essential medicines. This has been done via
creation of value-based insurance design in America [14]
and removal of copayments for all medicines in Scotland,
Wales and Northern Ireland [15,16]. However, full cover-
age for prescription medicines is linked with induced moral
hazard [17]. Therefore small, “symbolic” copayments have
been advocated [18]. Such copayments would, in theory,
represent a disincentive to partake of medicines that are
not necessary, while remaining cheap enough to facilitate
continued adherence to essential medicines.
Two qualitative studies of copayments for medicines
on the National Health Service (NHS) in the UK have
been carried out [19,20]. Both papers give valuable
insights into general opinions of cost-sharing and also
how patients deal with cost of medicines. The NHS and
GMS are similar in that both are tax funded public health
insurances. The populations of the UK and Ireland are
also culturally similar. However large differences exist; first
the copayment is much bigger on the NHS (£7.65 in 2012
in England). Secondly, the NHS provides healthcare to the
entire population whereas patients who qualify for the
GMS in Ireland would generally be exempt from NHS
prescription charges; therefore their views have not been
captured to date. An Italian copayment of €1.70 has been
explored in a cross country comparison between the NHS
of the UK and Italy [21]. However, as with the UK NHS,
the Italian NHS provides whole population coverage, in
contrast to the two-tiered health system in Ireland.
Despite this, it is interesting to note that Italians in this
study reported less affordability problems than UK
patients. An Australian qualitative study explored moral
hazard, however again the copayments are dissimilar tothe Irish copayment with pensioners paying $3.80 for pre-
scriptions in 2004 [22]. Furthermore, an increase in this
copayment in 2005 led to decreased dispensings of some
essential drugs; an unwanted feature of a limited copay-
ment policy [23]. Some American qualitative studies have
been carried out, however, they were focused on the logis-
tical challenges that patients were faced with when Medi-
care Part D was established,[24] concentrated on how
patients managed their medicines when taking multiple
drug regimens [25] or were concerned solely with the opi-
nions of mental health patients [26]. Even though there is
an extensive literature available on the quantitative effects
of copayments, and how this varies according to price paid
and medicines used, there is a limited qualitative literature
on examining public attitudes to small copayments. The
“symbolic” nature of the Irish copayment may be particu-
larly true given its small value in comparison to copay-
ments in other European countries [27,28].
The aim of this study is to address this gap in the lit-
erature by exploring the opinions of GMS patients
around whether 50 cent could be an appropriate limited
or “symbolic” copayment. Additionally, general opinion
and attitudes are investigated to gain relevant informa-
tion for Irish policy development.
Methods
Ethics
Ethical approval was sought from and granted by the
Clinical Research Committee of the Cork Teaching Hos-
pitals prior to initiating the study.
Interviewing method
This study is part of a larger project that will also quali-
tatively examine the views and opinions of GPs and
pharmacists and encompass a quantitative element using
a large national prescribing dataset. Therefore a qualita-
tive approach was taken in this instance to complement
the quantitative data; giving meaning and explanation
for any quantitative patterns observed.
Interviewing was chosen as the data collection method
for several reasons. First, issues around money and medi-
cines can be perceived as delicate topics; therefore discus-
sion in a focus group may be stilted. Secondly, interviews
provide advantages over focus groups in that in depth
coverage of a subject can be achieved as opposed to wider
superficial coverage in a focus group [29].
Interviews took place between January and March, 2012.
Participants
The sampling frame for this study was all GMS patients
attending a community pharmacy in the province of
Munster, Ireland. Patient views from 3 types of location
were required; an affluent urban area, a socially disad-
vantaged urban area and a rural area [30]. This sampling
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social circumstances, ages and gender. It was necessary to
locate pharmacies that were independently owned and
those that were part of a chain group, as there could be
subtle demographic differences in attenders at both types
of pharmacy (Table 1). Through personal contacts 5 phar-
macists were invited to participate in the study, all agreed
to be involved. Once pharmacist participation was agreed,
an interviewing date was agreed upon for one of two inter-
viewers to attend the pharmacy. Patients were conveni-
ently sampled from purposively sampled pharmacies [29];
that is pharmacists invited patients who presented at the
pharmacy on a given day to participate. Selection was not
based on prior knowledge of patient opinion towards the
charge or as representation of the pharmacist viewpoint.
Patients were free to decline participation in the study.
One patient did refuse inclusion in study because she did
not wish to be interviewed. This demonstrates patient au-
tonomy in participation and also minimization of selection
bias. Once patients agreed to be interviewed, the inter-
viewer explained who they were, clarified the aims and
objectives of the study and assured participants of anonym-
ity and data confidentiality. Participants were asked for ver-
bal consent which was recorded using a Dictaphone.Data collection
A topic guide for semi structured interviews was devel-
oped to gain information relevant to the study objective,
drawing on the existing literature and professional ex-
perience. Themes that were identified to be discussed
included knowledge of levy, opinion of levy, rational use
of medicines in relation to the levy and suggestions for
future policy formation. The guide was piloted with 2
pharmacists who advised modifications based on their
experiences with patients. Table 2 summarises the final
themes discussed. Interviews took place in pharmacies
instead of patient homes for reasons of access and expe-
dience. Pharmacy consultation areas provided confiden-
tial spaces to conduct interviews. Some interviews were
conducted in pharmacy seating areas, however it is not
anticipated that this had a negative impact on the quality
of data obtained. Interviews ranged in time from roughly
5 minutes to more than 30 minutes.Table 1 Distribution of Pharmacies by location and
pharmacy ownership status
Independent
pharmacy
Chain
pharmacy
Total
Affluent Urban 1 1
Socially Deprived Urban 1 1 2
Rural 1 1 2
Total 2 3 5No rigid rules exist for determining sample size in a
qualitative study. Generally, interviews are carried out
until no new material occurs in interviews, defined as
data saturation. While this is an accepted method in
qualitative research, there is no definitive test for satur-
ation of data. Francis et al. have proposed a method for
detecting data saturation [31]. This method involves,
first, identifying an “initial analysis sample” based on ap-
propriately sized sample sizes and second, defining the
“stopping criterion” – e.g., how many additional inter-
views will be carried out with no new themes emerging,
at which point data saturation can be declared. It was
decided that 20 interviews would be undertaken in this
study and then an additional 3 interviews were carried
out to test for data saturation. Data saturation appeared
to have occurred by the 19th interview, however interest-
ingly new material arose in the 20th and 23rd interviews.
Therefore, the traditional method of determining sample
size would have seen recruitment stop at the 19th inter-
view; however the Francis method in this case suggested
further recruiting until 3 consecutive interviews with
data saturation were obtained. Due to reasons of practi-
cality, further interviews were not conducted. It was
taken that repetition of themes in the 21st and 22nd inter-
views was adequate to satisfy traditional requirements of
data saturation.Analysis
The Framework approach was used to manage and ana-
lyse data, because its use is applicable in policy research
[29]. Data (transcripts) were inputted into QSR Interna-
tional’s NVivo 9.2 qualitative data analysis software [32].
The Framework method consists of five steps. The first
step of data familiarisation (reading and re-reading) oc-
curred from a very early stage due to data transcription.
The second step was drawing up a preliminary thematic
framework, which was informed by the topic guide and
emergent themes from interviews. This framework was
revisited and amended appropriately when all interviews
were completed. The framework was then applied to the
data and “tested for fit” which is the third step in the
framework method. The fourth stage involved the data
being charted (sorted and synthesised) on large matrices.
Language used by participants was used as much as pos-
sible at this stage to retain meaning and context in the
data. The last stage involved a more abstract process of
assigning higher meaning to charted data, pulling to-
gether core themes and providing associations and
explanations for these. Memo writing, while advocated
as a large part of Grounded Theory, was used in this
analysis [33]. The function of memo writing was to fa-
cilitate reflections on the data and provide an audit trail
of decision processes.
Table 2 Themes discussed in interviews
Demographic information
Knowledge of the purpose of the levy What do you know about the 50 cent levy?
Opinion on levy What did you feel when the government introduced a 50 cent levy on your prescription drugs?
Waste of prescription drugs What is your impression of waste when it comes to prescription drugs?
Effect of levy on medicine utilization Does the levy make you think any differently about collecting your medicines?
The levy as a barrier to utilization
Prioritisation of medicines Why would you leave some medicines out?
Effect of not taking medicines on health Are you aware of any side effects of not taking medicines?
Suggestions for policy
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A sample of 3 random indexed manuscripts was verified
by MG for accuracy of the thematic framework and ap-
plication of the framework to the transcripts. Some dis-
agreements in coding arose. The most common reason
for disagreement was redundant themes for the same
phenomenon e.g., empathy and relative affordabilities.
Through discussion these indexing discrepancies were
remedied [34].
Results
Twenty four people were interviewed (Table 3). One of
the 23 interviews involved 2 people, a husband and wife.
The dialogue between them added to the quality of the
data. Three different types of location were sampled
from in order to gain a spectrum of opinions.
The results of this study are spilt into 2 domains. The
first domain refers to how participant opinions and
insights relate to the Irish context. The second domain
alludes to how symbolic copayments could play a role in
reducing moral hazard, as perceived by members of the
GMS population, without implicating patient adherence
to important medicines.
Context specific to Ireland
General views on prescription charges
Generally, interviewees were supportive of the levy. There
was an overarching conditional acceptability; patients
appeared to be accepting of the charge, but would like
raised revenue to be used constructively. “Well it’s a good
idea if there’s something good going to be done with it like.
As long as it’s not just swallowed up with everything else”
04FJ.
In this group there was an underlying element of ap-
preciation for their medical cards “we’re lucky we have
our medical card” 06FJ. There was an awareness of fi-
nancial pressure within the government and this
appeared to ameliorate any potential feelings of unjust-
ness with the policy. Those who disagreed with the 50
cent levy were strongly opposed to it, not for reasons of
affordability, but for reasons of principle such as inequityand a sense of entitlement “After working all my life as a
xx. . ... I think I was after working for the medical
card”14MC. Issues of affordability arose when the levy
was discussed in combination with other recent charges
and levies in Ireland. Interestingly, some of those who
were opposed to the levy were located in rural and afflu-
ent areas, as opposed to socially disadvantaged areas.Small copayments as symbolic contribution
Patient determined causes of prescription medicine waste
A large proportion of patients identified the presence of
moral hazard within the realm of prescription drug supply
and demand. Many patients made references to people
who collect tablets they do not use properly or do not
need, allowing them to pile up at home. There was a feel-
ing that the prescription levy could play a role in reducing
this type of waste “I think with the levy now, people are
getting more clued in, when they have to pay. I think it’s a
great thing. Because people can say “oh God, I don’t need
that – I have that at home”10FC. Some participants were
cognoscente of the fact that the levy intentionally serves
to diminish moral hazard and perceived this positively
“. . .Cos people would get them for nothing, they‘d just
throw them there and take what they want. They’ve no re-
sponsibility like for what ‘tis costing. So I think it’s a good
thing in there. . .” 07 MJ.
There was conflicting opinion on whether the 50 cent
levy was effective in reducing this type of moral hazard.
It was acknowledged that some people who waste medi-
cines will continue to attend their pharmacy monthly
because of habit, forgetfulness or perhaps because of
loneliness. The opinion in this instance was that the 50
cent levy was not of sufficient financial worth to halt
wasteful use of medicines “if you’re the type that’s going
to stock up on pills the fifty cents isn’t going to stop you”
05FJ. In addition to this, the notion of a financial cost
adding value and encouraging use of medicines that
were previously wasted was disagreed with “but I mean,
if you need medication, this 50 cent per prescription
doesn’t really make the difference between whether that
Table 3 Characteristics of interviewees
Sex Male 9
Female 15
Frequency of age groups 31-40 1
41–50 2
51–60 8
61–70 3
>70 10
Geographic location Urban Deprived 8
Urban Affluent 4
Rural 12
Level of education Primary School 13
Secondary School 7
Third Level 2
Special School 1
Missing Data 1
Private health insurance Yes 4
No 19
Missing Data 1
Employment status Sheltered employment 1
Part Time Employment 2
Retired 10
Housewife 1
Unemployed 10
Length of time eligible for medical card <2 yrs 1
2-5 yrs 5
6-10 yrs 4
11-15 yrs 4
15-20 yrs 2
25-30 yrs 2
>30 yrs 3
Missing data 3
Number of medicines 1-2 5
3–4 3
5–6 5
7–8 4
9–10 4
11–12 1
13–14 1
>15 1
Types of medicines Oral hypoglcaemics, anti-hyperlipidaemics, anti-hypertensives, aspirin, nitrates, psychotropics, painkillers,
immunomodulators, osteoporotic agents, bronchodilators and inhaled steroids, gastric acid suppressants.
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no” 03 MJ
Other causes of prescription medicine waste
Conscientious prescribing was mentioned as a determin-
ing factor in accessibility to medicines. Most people
trusted that they would not be prescribed medications
unless they needed them and trusted their doctors to
make rational choices for them“. . ...Like I was told I’d
get now, since I got sick – if I was told to stand on my
head three times a day I would do it. . .” 05FJ
Potential waste in prescribing was described. Some
people mentioned that automatically generated prescrip-
tions often had unnecessary items on them. There was a
feeling that prescriptions should be subject to doctor re-
view and that the need for items on a prescription
should be discussed with the patient – in this way iden-
tification of drugs that are not working, or drugs that
patients have stopped using could occur, thus reducing
waste.
“. . ...should be a review anyways. . ...in terms of what
the doctor has on his records, and say ok “let’s do a
clean up here”, emmm “do you need this?”, “you don’t
really”. But. . .. . . sometimes and I know for a fact. . ...
that there isn’t a clean-up and it’s just happening
willy-nilly. So maybe if there was better practise in
terms of the doctor-patient interchange. . .. . .. . .then I
think it would tidy up a lot of excess. . .. . .” 24MD.
There was a sense that the 50 cent levy should in the-
ory encourage this type of prescription review by GPs,
but that in reality it does not.
Theorised negative effects of levy
In general, the 50cent levy did not appear to affect pa-
tient adherence to medicines, despite some being vehe-
mently opposed to the policy. One patient did stop
taking her cholesterol tablets for a period due to the cost
of the levy, however has since started to take them again
– this was thought to be a response to the principle of
the levy as opposed to the cost of it. Conversely, others
reported that they would sacrifice other goods first be-
fore not taking their medicines “. . .I wouldn’t be able to
go without my medication. I’d just have to actually cut
back on my food, or cut back on my household. . .” 06FJ.
Affordability of symbolic copayments
Overall there appeared to be limited problems with af-
fordability of the 50 cent copayment. Most participants
found the 50 cent to be financially acceptable – some
trivialised the cost comparing it to less than the price of
a bar of chocolate. There were 2 individuals, who al-
though did not explicitly admit financial difficulty withthe 50 cent levy, did discuss financial hardship repeat-
edly. “Well considering I’m on a low budget in a council
house. . .. I think t’was a bit harsh you know what I
mean, they should look at peoples’ backgrounds as well
as their medical conditions and just say, you know, help
them up” 17FC.
While financial hardship was mentioned in many of
the interviews; affordability issues seemed to revolve
around rising costs and charges for household bills, po-
tential septic tank inspections, and cutbacks in allowan-
ces for household heating. Therefore, disgruntlements
may be more associated with austerity at a broader level
as opposed to the 50 cent levy in particular.
“Well now it’s not the levy itself, it’s the other things
that are a tenner here, for my pension now, and a
tenner there, and a tenner everywhere. It’s not the
medicine, I’ve no qualms about paying for
medicine”07 MJ
Recommendations
The majority of interviewees felt that the 50 cent was a
reasonable amount for the levy, and that if it was left at
this people would continue to afford it. Those who were
opposed to the levy felt that it should be abolished. An
interesting theme of increased use of doctor services
arose on discussion of abolishing the levy.
“. . .. . .I’d probably be going to the doctor more often
with smaller things, you know. This way you don’t like,
you try to avoid the doctors like. . ...” 16FC
When asked about the possibility of a raised levy, most
people felt that a euro per item would be acceptable
whereas anything ranging from €2-€5 would be prohibi-
tive. There was an emergent sense of empathy as people
referred to how a raised levy would be unfair on those
with chronic illness. A very small number of people said
that their adherence to their medicines would be
affected by a raised charge, but most felt that their medi-
cines were too important to stop taking.
“. . .. . .I would have to take my medication because top
doctors have warned me like. So I would have to take
my medication on a regular basis. . .. . .”19MC
Discussion
This exploratory study provides a range of insights into
patients’ views on the 50 cent prescription levy. General
opinion and attitudes, cost-coping behaviours and aware-
ness of moral hazard, which are relevant to the Irish con-
text, echo those already found in the literature, even those
studies examining more expensive copayments [19-22].
The finding from this qualitative research of most interest
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pear to have accepted the prescription levy. Patients seem
to accept the levy because they are aware of increased fi-
nancial pressure within the health services and acknow-
ledge that wasteful use of drugs contributes to this
problem, a feature that has also been observed in inter-
national populations [20,35]. A sense of entitlement to free
medicines, after payment of taxes, was expressed, again
this has been reported elsewhere [20]. However, the
American literature highlights the fact that small copay-
ments do not impinge on perception that patients’ medical
needs are being catered for, a theme repeated in this study
nut only in those who are supportive of levy [35]. Intervie-
wees spoke at length about financial hardship and
expressed concern about rising charges and increasing
prices of household bills. However, worries were related to
the accumulation of charges as opposed to the prescrip-
tion levy in isolation.
Regarding the appropriateness of 50 cent as a suitable
symbolic copayment, it is worthwhile examining if
patients have experienced the negative implications of
cost-sharing, such as reduced adherence. In this qualita-
tive study of 24 participants, patients perceive necessity
of treatment to be more important than the cost of the
medicines to them. In addition, patients forecast the
negative effects of not adhering to medications and this
also appears to be a bigger determinant of medication
adherence than the 50 cent levy. That patients do not
allow cost alone to influence their medicine taking be-
haviour echoes previous qualitative findings [19,22,25].
However, given that this is a qualitative study – these
results cannot be generalised to whole populations espe-
cially in light of a plethora of large scale quantitative
studies which point to copayments effecting a reduction
in utilization [5,7]. Furthermore, quantitative evidence
points to reductions in utilisation seen in vulnerable
populations i.e., the poor, the elderly and the chronically
ill; groups which comprise the GMS population in Ire-
land [36-39].
A review article by Eaddy et al., shows the negative rela-
tionship between price paid for medicines and adherence
[8]. While copayment policies aim to reduce the use of
unnecessary medicines, there is a contemporaneous reduc-
tion in the use of essential medicines resulting in worsen-
ing patient adherence, subsequent poor health outcomes
and increased consumption of the health services [9-13].
Therefore, an ideal copayment would achieve an optimal
balance between a pecuniary value to halt moral hazard
associated with less-essential medicines and a value which
does not act as a disincentive to adherence to essential
medicines. This type of copayment would be advantageous
in that it can reduce government expenditure on unneces-
sary drug use, while generating “bonus” income from
copayment charges. The Beveridge type model of care thatis expected from patients [20,35] can also be maintained
with such copayments. Thus, from an international per-
spective, these results are of interest considering the small
value of the copayment and how this may relate to recent
advocacy for limited copayments [18,40].
The results of this study reveal inconclusive evidence for
50 cent being an approriate price of a copayment. Partici-
pants gave conflicting opinions on whether 50 cent would
halt moral hazard. Copayments work on the premise that
patients make rational decisions about what medicines are
less-essential. However, patients in this study were reluc-
tant to prioritise medicines and relied on their doctors to
make rational decisions for them. Patients appeared to
accept that if a doctor prescribed something then it was
necessary to take, this patient view has also been expressed
elsewhere [19,22]. Therefore, there may be a role for
health professionals such as general practitioners and
pharmacists to encourage patients to review their medi-
cines; indeed 1 patient proposed medicines use reviews
(MURs). MURs seek to increase patients’ understanding
of their medicines, reduce medication related morbidity,
and improve appropriate medicine taking. However, the
evidence for pharmacist led MURS in contracting costs is
not encouraging and they are sometimes met with patient
resistance [41,42]. Despite the poor evidence for pharma-
cists led MURS, the issue of prescribers being subject to
moral hazard has been discussed in the literature [20,43]
and is a factor that should be considered both in policy
development and by individual prescribers.
Most patients said they would not give up their medi-
cines due to a hypothetical price increase. It has been sug-
gested that patients who think they would forgo a tablet
because of clinical reasons e.g., unpleasant side effects, ac-
tually in real world circumstances stop taking their tablets
due to practical reasons such as cost [25]. Therefore patient
recommendations to increase the prescription levy should
be taken with heed. Likewise, recommendations to abolish
the levy could induce increased use of doctor services,
along with a loss of the associated financial advantages.
Limitations
Patients of a young age were not recruited to the study.
This may have occurred because data collection oc-
curred during work hours. This limitation demonstrates
a gap in the data collected, and highlights the need to in-
clude younger individuals in future qualitative studies on
this topic.
As mentioned in the methods section, a convenience
sample was used for data-collection. Concerns regarding
selection bias in recruitment are mediated by the fact
that the sample obtained is representative of the GMS
population, with a high number of older individuals
involved [44]. Patients were not fore-warned about inter-
views taking place and so did not have opportunity to
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the quality of the data and resulted in short interviews.
However, 23 interviews were carried out which limits
the impact of this drawback. In addition, interviews were
carried out in community pharmacies which are not a con-
ventional venue choice. Data acquisition was thought not
to be affected by venue type as opinions across a broad
spectrum were gathered; as opposed to one dominant
opinion which would be expected if individuals felt prohib-
ited from expressing themselves truthfully in this situation.
Furthermore, holding convenience interviews in a phar-
macy setting removed logistical barriers for participants.
Individuals who choose not to collect their prescrip-
tions because of the prescription charge cannot be
sampled and interviewed in a pharmacy setting. How-
ever, an interview did take place with one individual who
had stopped taking her medicine in the past due to the
cost; therefore insight into this situation was gained. Other
studies may choose to sample from a GP waiting room to
capture those that attend their GP but are primary non-
adherers [45]. However, as one interviewee pointed out;
when the prescription charge is in place people may
choose to avoid attending their doctor also.
The main researcher is a pharmacist and the second
interviewer was a final year pharmacy student, therefore
there was a possibility that patients gave socially desirable
responses. This bias was difficult to eliminate as the re-
search team felt that by disclosing the researchers’ back-
grounds to interviewees an element of professionalism
would be introduced into the interviews. It is difficult
to test for the presence of this bias. However given that
one participant felt comfortable in discussing her non-
adherence to cholesterol lowering medicine, it may be
taken that the interviewers established a solid rapport with
participants and socially desirable answers did not feature
dominantly in this study.Conclusions
The 2001 health policy document Quality and Fairness
– A health system for you [46] outlined that the Irish
health system would be one that “encourages you to have
your say, listens to you, and ensures that your views are
taken into account”
This study has allowed patients to express their views
and experiences with the 50 cent prescription levy. For
the most part, patients are willing to accept the copay-
ment. Patients have made valuable suggestions along
with highlighting areas that should be addressed to
achieve higher efficiency in controlling the drug budget,
such as rational prescribing. According to promises laid
out in Quality and Fairness, these views should now be
incorporated into any further policy development. Fur-
ther interviews with younger GMS patients and primarynon-adherers are required to capture the picture of the
broader population.
On a broader scale, the results of this study give some
direction in the search for the optimal copayment. There
was discordant opinion on whether 50 cent can halt
moral hazard. However, this should be considered along
with the fact that participants seem reluctant to sacrifice
medicines at this lower end of copayment scale. There
may be flexibility for increasing the levy. However, such a
policy move should first be supported by a large scale
quantitative analysis to assess the differential effect of the
50 cent copayment on essential and less-essential drugs be-
fore drawing any final conclusions on its appropriateness.
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